/

Società

Pi

Non verificato

Pint Pharma

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieSaluteVetrine/Shopping

3 comunicati stampa

Guarda tutti i comunicati

26/06/2025

Sanità

Farmaceutica

Salute

Industria

Pint Pharma Announces INVIMA’s Approval of ORLADEYO® (berotralstat), the First Oral Therapy for Preventing Hereditary Angioedema (HAE) Attacks in Patients Aged 12 and Older in Colombia

Fonte

Emittente

1.00

0

20/03/2025

Pint Pharma Announces ANVISA’s Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera

Fonte

Emittente

1.00

0

10/07/2024

Industria

Salute

Vetrine/Shopping

Biotecnologia

Medicina - Varie

Farmaceutica

Politica Locale

Pint Pharma announces the approval of ORLADEYO® (berotralstat), the first oral therapy indicated to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older in Peru.

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0